Recent literature about the treatment options of small cell lung cancer stresses the role of ifosfamide both alone and in combination with either cisplatin or carboplatin and etoposide. Its pharmacokinetics and the lower hematological toxicity permit the use of high doses which seem to be more effective in this very sensitive tumor. However, despite the increment in the response rate, in both limited and extended disease, the overall and long-term survival seems to be little influenced by therapy. Newer strategies combining old and new therapeutic approaches have to be explored to overcome the lack of progresses registered in these years.

Fukuoka M, Furuse K, Saijo N et al: Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 1991;83:855–861.
Einhorn LH, Crawford J, Birch R et al: Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small cell lung cancer. J Clin Oncol 1988;6:451–456.
Wolf M, Maasberg M, Pfab R, Havemann K: Combined chemo- and radiosensitivity testing with ifosfamide and ACNU in human lung cancer lines. J Cancer Res Clin Oncol 1991;117(suppl 4):187–192.
Nemati F, Livartowski A, De Cremoux P et al: Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts. Clin Cancer Res 2000;6:2075–2086.
Morgan LR, Posey LE, Rainey J et al: Ifosfamide: A weekly dose-fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep 1981;65:693–695.
Loehrer PJ, Birch R, Kramer BS et al: Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung. A Southeastern Cancer Study Group trial. Cancer Treat Rep 1986;70:919–920.
Warenius HM, Hurman DC, Cottier B: High-dose ifosfamide in small cell lung cancer. Br J Cancer 1986;54:216.
Drings P: Ifosfamide in the treatment of bronchial carcinoma. Contrib Oncol. Basel, Karger, 1987, vol 26, pp 294–318.
Cantwell BMJ, Bozzino JM, Corris P et al: The multidrug-resistant phenotype in clinical practice: Evaluation of cross-resistance to ifosfamide and mesna after VP-16, doxorubicin and vincristine (VPAV) for small cell lung cancer. Eur J Cancer Clin Oncol 1988;24:123–129.
Ettinger DS: The place of ifosfamide in chemotherapy of small cell lung cancer: The Eastern Cooperative Oncology Group experience and a selected literature update. Semin Oncol 1995;22(suppl 2):23–27.
Loehrer PJ, Lauer R, Roth BJ et al: Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988;109:540–546.
Wolf M, Havemann K, Holle R et al: Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small cell lung cancer: A multicenter German randomized trial. J Clin Oncol 1987;5:1880–1889.
Loehrer PJ, Ansari R, Gonin R et al: Cisplatin plus etoposide with and without ifosfamide in extensive small cell lung cancer: A Hoosier Oncology Group study. J Clin Oncol 1995;13:2594–2599.
Thatcher N, Lind M, Stout R et al: Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for ‘limited’ stage small cell carcinoma of the bronchus. Br J Cancer 1989;60:98–101.
Smith IE, Perren TS, Ashley SA et al: Carboplatin etoposide and ifosfamide as intensive chemotherapy for small cell lung cancer. J Clin Oncol 1990;8:899–905.
Prendiville J, Radford J, Thatcher N et al: Intensive therapy for small cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine and radiotherapy. J Clin Oncol 1991;9:1446–1452.
Thatcher N: Ifosfamide, carboplatin etoposide (ICE) regimen in small cell lung cancer. Lung Cancer 1993;9(suppl 1):51–67.
Wolff AC, Ettinger DS, Neuberg D et al: Phase II study of ifosfamide, carboplatin and oral etoposide chemotherapy for extensive-disease small cell lung cancer. An Eastern Cooperative Oncology Group study. J Clin Oncol 1995;13:1615–1622.
Arriagada R, Le Chevalier T, Pignon JP et al: Initial chemotherapeutic doses and survival in patients with limited small cell lung cancer. N Engl J Med 1993;329:1848–1852.
Humblet Y, Symann M, Bosly A et al: Late intensification chemotherapy with autologous bone marrow transplantation in selected small cell carcinoma of the lung: A randomized study. J Clin Oncol 1987;5:1864–1873.
Leyvraz S, Perey L, Rosti G et al: Multiple courses of high-dose ifosfamide, carboplatin and etoposide with peripheral blood progenitor cells and filgrastim for small cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999;17:3531–3539.
Arriagada R, Pignon JP, Le Chevalier T: Initial chemotherapeutic doses and long-term survival in limited small cell lung cancer. N Engl J Med 2001;345:1281–1282.
Turrisi AT, Kyungmann K, Blum R et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265–271.
Crawford J, Ozer H, Stoller R et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991;325:164–170.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.